Rznomics Presents Promising Interim Data for RZ-001 in Liver Cancer at AACR 2026
Rznomics, a clinical-stage biopharmaceutical company, has presented interim clinical data for its investigational anticancer therapy, RZ-001, at the American Association for Cancer Research (AACR) 2026 Annual Meeting in San Diego, California. The study focuses on patients with hepatocellular carcinoma (HCC) who are refractory to or ineligible for transarterial chemoembolization (TACE) and have not received prior systemic therapy. The data revealed that the combination of RZ-001 with atezolizumab and bevacizumab achieved an objective response rate (ORR) of 38.5% (confirmed) and 46.2% (unconfirmed) based on RECIST v1.1 criteria. Under mRECIST criteria, the ORR was 61.5%, with a complete response rate of 23%. Importantly, no Grade 3 or higher adverse events were attributed to RZ-001, indicating a favorable safety profile. 
